<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The endothelium: A primer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The endothelium: A primer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The endothelium: A primer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katherine A Hajjar, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William C Aird, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1854190"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endothelial cells (ECs) form the lining of all blood and lymphatic vessels within the vascular tree. The adult human body contains at least one trillion endothelial cells, which weigh more than 100 g and cover a surface area of more than 3000 square meters [<a href="#rid1">1,2</a>]. They therefore constitute a distributed organ that forms a dynamic interface with all other organs in the body.</p><p>The endothelium mediates vasomotor tone, regulates cellular and nutrient trafficking, maintains blood fluidity, contributes to the local balance between pro- and anti-inflammatory mediators as well as procoagulant and anticoagulant activity, participates in generation of new blood vessels, orchestrates organ development, participates in innate and acquired immunity, interacts with circulating blood cells, and undergoes programmed cell death [<a href="#rid3">3,4</a>]. Each of these activities is dynamically regulated in both space and time. Because endothelial cells receive cues from a wide variety of cells and tissues, they possess disparate properties that are specific to their local environment. Other phenotypic differences between endothelial cells are "locked in" by site-specific epigenetic mechanisms. Phenotypic heterogeneity is a central feature of the endothelium, and includes variations in morphology, biosynthetic repertoire, and behavior [<a href="#rid5">5</a>].</p><p>Here we review some of the general features of the endothelium [<a href="#rid6">6</a>].</p><p>Disease-specific considerations, which are presented separately, include:</p><p class="bulletIndent1"><span class="glyph">●</span>The cardiovascular system – (See  <a class="medical medical_review" href="/d/html/1532.html" rel="external">"Coronary endothelial dysfunction: Clinical aspects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary disorders – (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)"</a> and  <a class="medical medical_review" href="/d/html/8264.html" rel="external">"Inhaled nitric oxide in adults: Biology and indications for use", section on 'Biology and pharmacokinetics'</a> and  <a class="medical medical_review" href="/d/html/1609.html" rel="external">"Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults"</a> and  <a class="medical medical_review" href="/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy – (See  <a class="medical medical_review" href="/d/html/2794.html" rel="external">"Overview of angiogenesis inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes – (See  <a class="medical medical_review" href="/d/html/1756.html" rel="external">"Diabetic retinopathy: Pathogenesis", section on 'Growth factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obstetrical disorders – (See  <a class="medical medical_review" href="/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis", section on 'Role of systemic endothelial dysfunction in clinical findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection – (See  <a class="medical medical_review" href="/d/html/1597.html" rel="external">"Pathophysiology of sepsis", section on 'Circulation'</a> and  <a class="medical medical_review" href="/d/html/8315.html" rel="external">"Pathogenesis of hantavirus infections", section on 'Tissue tropism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematology – (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Adhesion of sickled cells to the vascular endothelium'</a> and  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"</a> and  <a class="medical medical_review" href="/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease", section on 'Bridging between platelets and vascular subendothelium'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatology – (See  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurology – (See  <a class="medical medical_review" href="/d/html/1285.html" rel="external">"Cerebrospinal fluid: Physiology and utility of an examination in disease states", section on 'Microbe entry in meningitis'</a>.)</p><p></p><p class="headingAnchor" id="H1854489"><span class="h1">THE ENDOTHELIUM FROM BENCH TO BEDSIDE</span><span class="headingEndMark"> — </span>Human endothelial cells were first propagated in culture in the early 1970s [<a href="#rid7">7</a>]. Although there have been major subsequent advances in our understanding of endothelial cell (EC) biology based upon this critically important technology, it is still apparent that ECs tend to dedifferentiate and lose their specialized characteristics in culture. </p><p>In past decades, limitations to studying ECs in vivo have included the absence of effective imaging techniques, the dearth of suitable biomarkers reflecting their biologic behavior, and their distinct structural and functional heterogeneity.</p><p>Subsequently, single cell multiomic analyses of capillary ECs have revealed precise profiles in gene expression and chromatin accessibility [<a href="#rid8">8</a>]. Such gene expression profiles can explain cellular architecture, tissue-specific signaling, and metabolic pathways, and they have identified marker genes associated with organ-specific vascular subtypes. New multiomic EC atlases will likely pave the way for targeted EC therapies as well as the rational design of organ-specific vascular networks for tissue engineering and possibly organ replacement. </p><p class="headingAnchor" id="H1854496"><span class="h1">ENDOTHELIAL HETEROGENEITY</span></p><p class="headingAnchor" id="H1854504"><span class="h2">Complex signaling patterns</span><span class="headingEndMark"> — </span>Endothelial cells (ECs) receive and respond to signals from both surrounding cells and tissues, and flowing blood. Afferent signals are provided by soluble mediators, cell contacts, changes in oxygenation, hemodynamic forces, temperature, and pH. Efferent responses modulate vasomotor tone, vascular permeability, hemostatic balance, inflammatory signals, as well as cellular proliferation and survival. The response of the EC to a given stimulus may vary dramatically from one vascular bed to another, over time, and depending on environmental stimuli [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H1854511"><span class="h2">Structural specializations</span><span class="headingEndMark"> — </span>In different vascular beds, ECs develop discrete ultrastructural specializations [<a href="#rid10">10</a>]. In the central nervous system, for example, the endothelium is "continuous" with complex tight junctions that form the blood-brain barrier. ECs in the endocrine glands and renal glomeruli are "fenestrated," with transcellular pores that permit hormone protein secretion and plasma filtration. ECs that allow the exchange of cells or particles are "discontinuous", displaying gaps between adjacent cells and poorly formed underlying basement membrane; these cells typify sinusoids of the liver, spleen, and bone marrow.</p><p class="headingAnchor" id="H1854527"><span class="h2">Temporal variations</span><span class="headingEndMark"> — </span>In a given vascular bed, EC properties differ from one moment to the next as they respond to physiologic and pathophysiologic stimuli [<a href="#rid11">11-14</a>]. Both spatial and temporal heterogeneity contribute to the frequently focal nature of vasculopathic disease states.</p><p class="headingAnchor" id="H1854534"><span class="h2">Changing synthetic repertoires</span><span class="headingEndMark"> — </span>Advances in genomics and proteomics have uncovered an expansive array of site-specific properties of the endothelium [<a href="#rid15">15-18</a>]. These characteristics reflect differences in programs of protein synthesis, and result from specific signals that originate in the surrounding cells and tissues.</p><p>The following three examples show how this variability may be clinically relevant:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anatomic variation</strong> – The procoagulant/anticoagulant balance appears to differ between the endothelium of the venous valvular sinus and vein lumen, with the valvular sinus endothelium displaying decreased expression of von Willebrand factor [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular bed variation</strong> – In patients with thrombotic thrombocytopenic purpura (TTP), differences in vascular endothelial damage might reflect the fact that CD36, the thrombospondin receptor, is found on human microvascular ECs (HMVEC), but not ECs of large (umbilical) vessels (HUVEC). (See  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)", section on 'Histopathology of TMA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temporal variation</strong> – In a transgenic mouse model of sickle cell disease (SCD), EC expression of tissue factor was confined almost exclusively to the pulmonary veins [<a href="#rid20">20</a>]. This expression increased significantly following exposure of the mild SCD mouse models to one cycle of hypoxia/reoxygenation, converting the phenotype to that of the severe SCD mouse.</p><p></p><p class="headingAnchor" id="H1854541"><span class="h1">PATTERNS OF CHANGE IN ENDOTHELIAL FUNCTION</span></p><p class="headingAnchor" id="H1854549"><span class="h2">EC activation</span><span class="headingEndMark"> — </span>Originally, the term "endothelial cell activation" was based on the observation that cultured endothelial cells (ECs) demonstrated increased leukocyte adhesion following exposure to inflammatory mediators. The term was expanded later to embrace a wider spectrum of phenotypic changes, including decreased thromboresistance, altered vasomotor tone, and loss of barrier function. According to this paradigm, quiescent ECs display a thromboresistant, anti-adhesive and vasodilatory phenotype, whereas activated ECs have procoagulant, pro-adhesive, and vasoconstricting properties.</p><p>However, to avoid oversimplification with regard to the state of EC activation, it is important to remember the following points:</p><p class="bulletIndent1"><span class="glyph">●</span>The phenotypic spectrum of ECs is a dynamic continuum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activation for one type of EC may not meet the definition of activation at another site. For example, non-inflamed skin venules express P-selectin constitutively [<a href="#rid21">21</a>], whereas venules from other sites (eg, the mesentery) express P-selectin only when activated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory mediators such as tumor necrosis factor-alpha, thrombin, and lipopolysaccharide may have distinct or only partially overlapping effects on EC phenotypes [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EC activation is not an all-or-nothing response, nor is it necessarily linked to disease. Normal endothelium is highly responsive to alterations in the local extracellular milieu. Such environmental changes might occur in the setting of transient bacteremia, minor trauma, and other common stresses (eg, small temperature changes, proteolytic activity, and shear stress), and can be transient and mild or sustained and severe.</p><p></p><p class="headingAnchor" id="H1854563"><span class="h2">EC dysfunction</span><span class="headingEndMark"> — </span>EC dysfunction, broadly understood, is a feature of the aging vasculature [<a href="#rid23">23</a>]. Initially, EC dysfunction referred to EC structural changes, loss of integrity, or hyper-adhesiveness of the vascular lining toward platelets as might be seen in atherosclerosis [<a href="#rid24">24-26</a>]. Over time, the term came to reflect the loss of the endothelium's ability to regulate vascular resistance. More recently, the term EC dysfunction has been broadly applied to states in which the EC phenotype, whether or not it meets the definition of activation, poses a net liability to the host. Examples include severe sepsis (see <a class="local">'Severe sepsis'</a> below), pulmonary hypertension, pathological angiogenesis, thrombotic thrombocytopenic purpura, hepatic veno-occlusive disease, and sickle cell disease.</p><p class="headingAnchor" id="H1854578"><span class="h2">Nitric oxide production</span><span class="headingEndMark"> — </span>The principal physiologic stimulus for endothelial nitric oxide (NO) synthesis is blood flow-induced shear stress, a process termed "flow-mediated vasodilatation" (see  <a class="medical medical_review" href="/d/html/1538.html" rel="external">"Coronary artery endothelial dysfunction: Basic concepts", section on 'Nitric oxide function'</a>). In addition, a variety of agonists, including acetylcholine, histamine, thrombin, serotonin, adenosine diphosphate, bradykinin, and norepinephrine, can increase the synthesis and release of NO. These agonists result in vasorelaxation when the endothelium is intact, and vasoconstriction if the endothelium is removed or perturbed.</p><p>NO has a number of other effects. It inhibits platelet adhesion and aggregation, an effect that may be synergistic with that of prostacyclin. NO blocks monocyte adhesion to the endothelium. NO also reduces endotoxin- and cytokine-induced expression of tissue factor, thus modulating the prothrombotic potential of the endothelial cell.</p><p>Paradoxical vasoconstriction of coronary arteries induced by acetylcholine was described in early and advanced human atherosclerosis. The current belief is that an abnormal vascular response to acetylcholine may represent a defect in EC vasodilator function, due at least in part to reduced EC production of NO [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H1854585"><span class="h2">Leukocyte adhesion to endothelium</span><span class="headingEndMark"> — </span>A pathophysiologic link has been made between inducible endothelial-leukocyte adhesion molecules and atherosclerosis (so-called athero-ELAMs) via the identification of an inducible endothelial cell-specific antigen that binds predominantly to monocytes [<a href="#rid28">28</a>]. Peptide sequencing revealed homology to the predicted sequence of human vascular cell adhesion molecule (VCAM)-1, which had been previously cloned as a cytokine-inducible protein in endothelial cells [<a href="#rid29">29</a>]. Subsequently, VCAM-1 was localized to the endothelium overlying atherosclerotic lesions in a hyperlipidemic rabbit model [<a href="#rid28">28</a>] and was shown to be a risk factor for venous thrombosis in a kindred with protein C deficiency [<a href="#rid30">30</a>]. These observations not only emphasized the role of endothelial dysfunction as a primary determinant of atherosclerosis, but also helped to refocus research and development on the inflammatory nature of this disease process.</p><p>Additional details regarding leukocyte-endothelial interactions in the pathogenesis of inflammation are presented separately. (See  <a class="medical medical_review" href="/d/html/3983.html" rel="external">"Leukocyte-endothelial adhesion in the pathogenesis of inflammation"</a>.)</p><p class="headingAnchor" id="H713164446"><span class="h2">Interactions with the hemostatic system</span><span class="headingEndMark"> — </span>ECs produce a wide array of thromboregulators that act at both early and late stages of thrombus formation [<a href="#rid31">31</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Early regulators include the endothelial eicosanoid prostacyclin (PGI2) and nitric oxide, both of which inhibit platelet reactivity and induce vascular relaxation, and extracellular adenosine triphosphate diphosphohydrolase (ectoADPase-1), which prevents further platelet recruitment. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Formation of the platelet plug'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late acting thromboregulators include natural anticoagulants such as antithrombin, which inhibits thrombin and factor Xa; tissue factor pathway inhibitor (TFPI), which blocks complex formation between factor VIIa and tissue factor; and the thrombomodulin/endothelial cell protein C receptor (EPCR)/protein C system, which inactivates procoagulant factors. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Control mechanisms and termination of clotting'</a>.)</p><p></p><p>Endothelial cells are associated with the fibrinolytic system, as they synthesize and secrete tissue plasminogen activator (tPA) and assemble plasmin forming molecules through expression of key receptors on their surface, such as the annexin A2 complex. Deficiency of annexin A2 was associated with increased incidence of venous thromboembolic disease in one study [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Clot dissolution and fibrinolysis'</a>.)</p><p class="headingAnchor" id="H2212843531"><span class="h1">COVID-19 AND ENDOTHELIAL INJURY</span><span class="headingEndMark"> — </span>Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, is a multisystem inflammatory disease [<a href="#rid33">33-35</a>] characterized by increasingly severe hypoxia, pulmonary vascular leak, cytokine storm, and multiorgan failure, especially in individuals with pre-existing vascular injury associated with diabetes, hypertension, atherosclerosis, or a history of smoking [<a href="#rid33">33-35</a>]. </p><p>In severe COVID-19, microvascular thromboinflammation and potentially catastrophic macrovascular venous thromboembolism can occur, involving lungs, kidneys, heart, and other organs [<a href="#rid36">36</a>]. Autopsy reports indicate a pauci-inflammatory capillary injury, also referred to as endotheliitis, with fibrin deposition and activation of terminal components of complement, including C5b-9, C4b, and mannose-binding lectin-associated serine [<a href="#rid37">37-39</a>]. Endothelial injury is one of the three major contributors to hypercoagulability. (See  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability", section on 'Virchow's triad'</a>.)</p><p class="headingAnchor" id="H1854645"><span class="h1">SEPSIS AS A MODEL ENDOTHELIOPATHY</span><span class="headingEndMark"> — </span>Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [<a href="#rid40">40</a>]. Sepsis is a common and often fatal disorder in which changes in endothelial function play a central role [<a href="#rid41">41,42</a>]. The assault on the endothelium occurs on three separate fronts [<a href="#rid43">43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pathogens may directly infect endothelial cells (ECs) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Components of the bacterial cell wall (eg, lipopolysaccharide [LPS]) may activate pattern recognition receptors on the surface of the EC [<a href="#rid45">45-48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Host-derived products (eg, complement, cytokines, chemokines, serine proteases, fibrin, activated platelets and leukocytes, elevated glucose, reactive oxygen species or hypoxia-induced factors, and hemodynamic changes) may activate ECs [<a href="#rid49">49</a>].</p><p></p><p>The endothelium responds to these stresses in ways that differ according to the nature of the pathogen, host genetics, underlying comorbidity, age, sex, and the location of the vascular bed. These responses may include structural changes, such as nuclear vacuolization, cytoplasmic swelling, cytoplasmic fragmentation, denudation, and/or detachment [<a href="#rid50">50</a>]. However, functional changes in the endothelium are even more common and include shifts in hemostatic balance, increased leukocyte adhesion and trafficking, altered vasomotor tone, loss of barrier function, and programmed cell death.</p><p class="headingAnchor" id="H1854652"><span class="h2">Procoagulant properties</span><span class="headingEndMark"> — </span>Inflammatory mediators may interact with ECs to induce a loss of the normal thromboresistant phenotype. In cultured endothelial cells, addition of bacterial lipopolysaccharide and/or cytokines results in a series of procoagulant responses [<a href="#rid41">41,42</a>] including decreased synthesis of thrombomodulin (TM), tissue-type plasminogen activator and heparan sulfate, increased expression of tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1), and generation of procoagulant microparticles [<a href="#rid51">51</a>]. (See <a class="local">'Interactions with the hemostatic system'</a> above.)</p><p>In whole animal models of sepsis, however, the endothelium does not express detectable TF with the possible exception of the spleen and aorta [<a href="#rid52">52,53</a>]. Moreover, while the association of sepsis and decreased levels of TM has been confirmed in the skin vasculature [<a href="#rid54">54</a>], this phenomenon does not apply to all vascular beds. ECs of the blood brain barrier, for example, do not normally express TM [<a href="#rid55">55</a>].</p><p>In vivo, properties of ECs that may contribute to the sepsis-associated procoagulant state include recruitment of platelets, monocytes, and neutrophils, all of which are capable of initiating or amplifying coagulation; cell surface translocation of anionic phospholipids that enhance the binding of coagulation complexes; increased exposure of subendothelium (eg, collagen, fibronectin, fibrinogen, von Willebrand factor), which may serve as attachment sites for platelets as ECs undergo apoptosis [<a href="#rid56">56,57</a>]; and development of a low flow state, as a result of reduced cardiac output, vasoconstriction, or occlusive lesions, leading to reduced clearance of activated procoagulant serine proteases, thus promoting additional clotting.</p><p>Evidence that increased endothelial cell anticoagulant activity can reverse the coagulopathy associated with LPS administration comes from a transgenic mouse model. When either the leech anticoagulant hirudin or human tissue factor pathway inhibitor (TFPI) was expressed on endothelial cells, monocytes, and platelets, widespread intravascular thrombosis, thrombocytopenia, and coagulopathy were inhibited [<a href="#rid58">58</a>]. While it does not describe a clinically-relevant approach, this study supports the postulate that modulation of endothelial cell properties can modify the clinical expression of endotoxemia.</p><p class="headingAnchor" id="H1854672"><span class="h2">Disseminated intravascular coagulation</span><span class="headingEndMark"> — </span>Virtually all patients with severe sepsis have activation of the coagulation cascade. Initiation of clotting is thought to reflect expression of tissue factor on the surface of activated monocytes and macrophages, with subsequent induction of increased thrombin generation, and fibrin formation. In the extreme, this leads to depletion of coagulation factors, disseminated intravascular coagulation (DIC), and possible end-organ damage. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.)</p><p>The extent to which the above changes occur in the intact endothelium is not entirely clear. As with other properties of the endothelium, the hemostatic balance is differentially regulated among the various vascular beds. In a baboon sepsis model, for example, administration of lethal doses of E. coli resulted in increased fibrin deposition in the marginal zone and sinusoids of the spleen, hepatic sinusoids, glomeruli, and peritubular vessels of the kidney, but little or no fibrin in the portal vessels of the liver, cerebral cortex, skin, myocardium, or aorta [<a href="#rid52">52</a>]. These results, and similar data obtained in mouse models of sepsis, point to a predilection for organ-specific coagulation in sepsis. Their clinical relevance is supported by studies of cerebral malaria in which malaria-associated depletion of endothelial protein C receptor (EPCR), with subsequent impairment of the protein C system, promotes a proinflammatory, procoagulant state in brain microvessels [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H1854692"><span class="h2">Genetic influences</span><span class="headingEndMark"> — </span>In mice with genetically determined hypercoagulable states, sepsis results in a marked shift in hemostatic balance in ways that differ between vascular beds. For example, in mice that carry a thrombomodulin (TM) gene mutation, disruption of the TM-dependent activation of protein C via the administration of lipopolysaccharide (LPS) resulted in higher levels of fibrin deposition in the lung and kidney, but not the brain, compared with wild-type mice [<a href="#rid60">60</a>]. In contrast, in heterozygous antithrombin-deficient mice, LPS challenge resulted in increased deposition of fibrin in the kidney, liver, and heart [<a href="#rid61">61</a>]. These studies demonstrate the importance of underlying genetics in the sepsis phenotype. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Activated protein C and protein S'</a>.)</p><p class="headingAnchor" id="H1854712"><span class="h2">Pro-adhesive properties</span><span class="headingEndMark"> — </span>In some endothelia, inflammatory mediators induce expression of adhesion molecules such as P-selectin [<a href="#rid62">62</a>], E-selectin, intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1. These alterations are particularly prominent on post-capillary venules [<a href="#rid63">63,64</a>], and result in increased rolling, adherence, and transmigration of leukocytes into underlying tissue. (See  <a class="medical medical_review" href="/d/html/3983.html" rel="external">"Leukocyte-endothelial adhesion in the pathogenesis of inflammation"</a>.)</p><p>Activated ECs also recruit increased numbers of platelets to the blood vessel wall. This process may contribute to vaso-occlusive crises in patients with sickle cell disease by promoting adhesion of red cells. (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Adhesion of sickled cells to the vascular endothelium'</a>.)</p><p>Similarly, upregulation of platelet activating factor (PAF) receptors on chronically activated ECs may predispose patients with sickle cell disease to invasive pneumococcal infection. (See  <a class="medical medical_review" href="/d/html/7023.html" rel="external">"<i>Streptococcus pneumoniae</i>: Microbiology and pathogenesis of infection", section on 'Invasion'</a>.)</p><p class="headingAnchor" id="H1854776"><span class="h2">Vasomotor properties</span><span class="headingEndMark"> — </span>Vasomotor tone is regulated through a combination of endothelial-dependent and -independent mechanisms. ECs produce vasoactive molecules that regulate arteriolar tone and contribute to blood pressure control. These factors include both vasodilators (eg, nitric oxide [NO], prostacyclin) and vasoconstrictors (eg, endothelin, thromboxane A2, and platelet-activating factor). (See  <a class="medical medical_review" href="/d/html/8264.html" rel="external">"Inhaled nitric oxide in adults: Biology and indications for use"</a>.)</p><p>NO levels are elevated during sepsis and appear to play a complex role in the associated vascular pathology [<a href="#rid65">65,66</a>]. It has been suggested that red blood cells may directly mediate systemic vascular relaxation and hypotension in sepsis through NO-dependent mechanisms [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins", section on 'Nitric oxide transport'</a>.)</p><p class="headingAnchor" id="H1854796"><span class="h2">Increased permeability</span><span class="headingEndMark"> — </span>In the intact vasculature, the endothelium forms a continuous, semipermeable barrier that varies in integrity in different vascular beds. A central feature of the endothelium in sepsis is its increased permeability and loss of barrier function, resulting in extravasation of circulating elements and tissue edema [<a href="#rid68">68</a>]. Several proteins contribute to this phenomenon:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor necrosis factor (TNF)-alpha</strong> induces an increase in EC permeability both in vitro and in vivo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombin</strong> increases EC permeability in vivo, while TNF-alpha and thrombin act synergistically to induce barrier dysfunction in vitro.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular endothelial growth factor (VEGF)</strong>, which is produced by several different cell types, acts on vascular endothelial cells to stimulate angiogenesis. VEGF induces EC proliferation, survival and directed migration, while it also increases vascular permeability. VEGF is 50,000 times more potent in inducing vascular leakage than histamine. VEGF levels are elevated in sepsis, and VEGF has been shown to play a pathogenic role in mouse models of sepsis [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/2794.html" rel="external">"Overview of angiogenesis inhibitors", section on 'Vascular endothelial growth factor'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiopoietin 2 (ANGPT2)</strong>, which is rapidly released from Weibel-Palade bodies in states of inflammation, attenuates Tie-2 signaling in endothelial cells, resulting in enhanced barrier disruption. ANGPT2 levels are elevated during sepsis and have been shown to predict development of shock and death [<a href="#rid70">70,71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycocalyx</strong>, a major proteoglycan-containing constituent of the endothelial surface layer that limits the access of cells and solutes to the surface of the endothelium and contributes to cell signaling, may become degraded in sepsis, leading to increased permeability [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endothelial junction proteins</strong> such as vascular endothelial cadherin (VE-cadherin), vascular endothelial protein tyrosine phosphatase, and Src-homology phosphatase 2 (SHP2) regulate adherens-like inter-endothelial junctions. In the lung, but not in other tissues, annexin A2 promotes microvascular integrity by enabling dephosphorylation of VE-cadherin [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Annexin A2</strong> is a membrane-binding protein that recruits key phosphatases to endothelial-endothelial cell junctions formed by homotypic VE-cadherin interactions. VE-protein tyrosine phosphatase and Src homology phosphatase prevent over-phosphorylation of VE-cadherin, thereby maintaining closed inter-endothelial junctions and preventing vascular leak under hypoxia. This mechanism is active primarily in the lung but not in other organ microvascular beds [<a href="#rid74">74</a>].</p><p></p><p class="headingAnchor" id="H1854816"><span class="h2">EC apoptosis</span><span class="headingEndMark"> — </span>Normally, less than 0.1 percent of all ECs are apoptotic. However, certain pathogens are capable of inducing EC apoptosis in vitro, and a host of mediators that are produced during sepsis may induce EC apoptosis. These include TNF-alpha, interleukin (IL)-1, interferon, oxygen-containing free radicals, and hypoxia. In addition, LPS-activated monocytes promote programmed cell death in ECs by a combination of TNF-alpha-dependent and -independent mechanisms [<a href="#rid75">75</a>].</p><p>EC apoptosis results in an accentuated proinflammatory response. Under in vitro conditions, apoptotic ECs mediate IL-1-dependent paracrine induction of ICAM-1 and VCAM-1, increased production of reactive oxygen species, increased procoagulant activity, decreased production of prostacyclin, and complement activation. ECs undergoing apoptosis also demonstrate increased binding to nonactivated platelets [<a href="#rid76">76</a>].</p><p>In a mouse model of endotoxemia, intraperitoneally delivered LPS resulted in widespread apoptosis of the endothelium, while in other studies, the intravenous administration of LPS induced EC apoptosis in the lung, but not the liver, again demonstrating organ-specific differences in endothelial response.</p><p class="headingAnchor" id="H1854833"><span class="h2">Local versus systemic endothelial activation</span><span class="headingEndMark"> — </span>The innate host response evolved as a local mechanism to eradicate pathogens and necrotic tissue. The endothelium orchestrates this response by promoting the adhesion and transmigration of leukocytes, inducing thrombin generation and fibrin formation, altering local vasomotor tone, increasing vascular permeability, and triggering programmed cell death [<a href="#rid77">77</a>]. Normally, this is a compartmentalized process.</p><p>However, when the host endothelial response becomes generalized, a dysregulated, inflammatory response ensues. Such widespread endothelial involvement may lead to the systemic inflammatory response syndrome (SIRS) and/or the multiple organ dysfunction syndrome (MODS). (See  <a class="medical medical_review" href="/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"</a>.) Endothelial cell dysfunction in sepsis arises from an otherwise adaptive response. Therefore, targeting the host response too early may worsen patient outcome. Indeed, it is tempting to speculate that some of the failures in sepsis trials may be related to inadvertent interference with adaptive mechanisms.</p><p class="headingAnchor" id="H3188235639"><span class="h2">Immunomodulation</span><span class="headingEndMark"> — </span>Single cell analyses have revealed a much greater role for ECs in innate immunity than was previously thought. Transcriptional profiling studies suggest that ECs can demonstrate phagocytic activity, antigen presentation capability, and cytokine production for immune cell recruitment [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/d/html/3982.html" rel="external">"Antigen-presenting cells"</a> and  <a class="medical medical_review" href="/d/html/13572.html" rel="external">"An overview of the innate immune system"</a>.)</p><p>These properties appear to vary by the type of tissue and type of blood vessel. ECs may therefore serve as new therapeutic targets for immunomodulation.</p><p class="headingAnchor" id="H3530033"><span class="h1">COMPLEMENT-MEDIATED ENDOTHELIAL CELL INJURY</span><span class="headingEndMark"> — </span>Endothelial cells express a range of complement receptors and complement regulatory proteins, and are subject to attack by complement [<a href="#rid79">79</a>]. The C5b-9 membrane attack complex (MAC) can induce endothelial cell lysis, while sub-lytic amounts of MAC may activate the cells to release proinflammatory P-selectin and procoagulant von Willebrand factor, and may also disturb normal endothelial cell barrier function [<a href="#rid80">80</a>]. Examples of the clinical use of anti-complement therapies in endothelial disorders include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Complement-mediated thrombotic microangiopathy (TMA), also called complement-mediated hemolytic uremic syndrome (HUS), is associated with mutations or autoantibodies that lead to excessive complement activation. Renal endothelial cells appear to be especially sensitive to complement-mediated injury, thus providing a possible rationale for the efficacy of complement inhibition in this setting. The treatment of complement-mediated TMA with anti-complement therapy is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In antibody-mediated transplant rejection, antibodies directed against endothelial cell antigens, most often HLA-A, B, C and DR, may kill or disable endothelial cells by excessive activation of complement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In age-related macular degeneration, a major cause of blindness, polymorphisms in the allele for complement factor H (CFH) account for approximately 43 to 50 percent of the disease in older adults; it is hypothesized that these changes impair the ability of CFH to suppress complement activation and hence endothelial cell damage. (See  <a class="medical medical_review" href="/d/html/6901.html" rel="external">"Age-related macular degeneration", section on 'Pathogenesis'</a>.)</p><p></p><p class="headingAnchor" id="H1854852"><span class="h1">EVALUATION OF ENDOTHELIAL DISORDERS</span><span class="headingEndMark"> — </span>One approach to studying endothelial cell (EC) function in vivo involves the use of strategically placed catheters that allow the examiner to sample blood from a specific vascular bed. Thus, coronary endothelial function can be evaluated in humans by selective infusion of acetylcholine into the epicardial coronary arteries, followed by measurement of vessel diameter and Doppler-derived velocity to calculate coronary blood flow. Using this technique, studies have revealed that coronary endothelial dysfunction is common in patients with coronary artery disease [<a href="#rid27">27</a>].</p><p>In addition, newer proteomics techniques are likely to provide novel platforms (eg, protein-based chips) that will allow the practitioner to simultaneously monitor a panel of endothelial cell function biomarkers. For example, proteomics may be valuable in determining the presence or absence of specific complications (eg, graft versus host disease or sepsis) in patients undergoing hematopoietic cell transplantation [<a href="#rid81">81</a>], in understanding changes in blood-brain barrier function in central nervous system disease [<a href="#rid82">82,83</a>], or in assessing the pathologic mechanisms in stroke [<a href="#rid84">84</a>]. By extension, a more comprehensive and systematic analysis of pathological specimens (eg, skin biopsies) might provide even more robust data that reflect EC function.</p><p>Imaging studies, such as Doppler measurements of blood flow, magnetic resonance angiography and computed tomography (CT) scanning are widely available in clinical practice and should be applicable to the study of EC (dys)function. Molecular imaging, which combines the power of proteomics with advanced labeling techniques, could revolutionize the diagnosis of endothelial-based disorders [<a href="#rid85">85,86</a>].</p><p class="headingAnchor" id="H1854872"><span class="h2">Circulating endothelial cells</span><span class="headingEndMark"> — </span>Refined protocols to isolate and interrogate the phenotype of circulating endothelial cells (CEC) and their progenitors may yield insight into their function or their bed-of-origin [<a href="#rid87">87-95</a>]. Thus, measurement of a panel of activation markers, rather than a single mediator, may yield previously unappreciated response patterns that will aid in diagnosis, monitoring, and/or treatment of vascular and coagulation disorders [<a href="#rid90">90,96,97</a>].</p><p class="headingAnchor" id="H1854880"><span class="h2">Microparticles</span><span class="headingEndMark"> — </span>Microparticles may possibly serve as a means of intercellular communication in hemostasis and vascular biology [<a href="#rid98">98</a>]. Microparticles are vesicles of submicron size that are shed from plasma membranes in response to cell activation, injury, or apoptosis [<a href="#rid99">99</a>]. Although still in the development stage, enumeration of microparticles before and during treatment may prove helpful in revealing the degree of endothelial damage, as well as their response to treatment in various disorders involving microvascular injury [<a href="#rid100">100-106</a>]. (See  <a class="medical medical_review" href="/d/html/1353.html" rel="external">"Cancer-associated hypercoagulable state: Causes and mechanisms", section on 'Biomarkers'</a>.)</p><p class="headingAnchor" id="H1489047861"><span class="h2">Peripheral venous endothelial cell biopsy</span><span class="headingEndMark"> — </span>Protocols are available for obtaining endothelial cells from peripheral veins; these cells can be plated on poly-L-lysine coated microscope slides, treated in the absence or presence of agonists, and assayed for protein or mRNA expression. This approach has been used to provide evidence for the presence of altered eNOS activation, reduced insulin action, and inflammatory activation in the endothelium of patients with diabetes mellitus [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H1489047868"><span class="h2">Blood outgrowth endothelial cells</span><span class="headingEndMark"> — </span>Blood outgrowth endothelial cells (BOECs; also called late outgrowth endothelial progenitor cells or endothelial colony-forming cells) are bone marrow-derived stem cells that have the ability to differentiate into mature ECs [<a href="#rid108">108</a>]. They can be cryopreserved, subjected to gene transfer, and further expanded for vascular repair. They have been implicated in postnatal vasculogenesis and endothelial repair at sites of endothelial damage. These cells have been isolated from patients with several endothelial-based diseases, including von Willebrand disease and sickle cell disease, where they have provided important new insights into underlying pathophysiology and diagnosis [<a href="#rid109">109-112</a>].</p><p class="headingAnchor" id="H1854887"><span class="h1">TREATMENT OF ENDOTHELIAL DISORDERS</span><span class="headingEndMark"> — </span>The endothelium is an attractive therapeutic target:</p><p class="bulletIndent1"><span class="glyph">●</span>It is strategically located between the circulating blood and every tissue, and is therefore rapidly and preferentially exposed to systemically administered agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As a result of its high degree of plasticity, it should be amenable to therapeutic manipulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Due to its close proximity to underlying tissues, the endothelium provides a direct line of communication to all organs of the body.</p><p></p><p>Some examples of endothelial cell (EC)-targeted therapies are outlined below.</p><p class="headingAnchor" id="H1854605"><span class="h2">Severe sepsis</span><span class="headingEndMark"> — </span>Endothelial function is altered in sepsis, and enormous resources have been expended on sepsis trials, with more than 10,000 patients enrolled in over 20 randomized trials. In patients with severe sepsis, most therapies, including anti-endotoxin, anti-cytokine, anti-prostaglandin, anti-bradykinin, anti-platelet activating factor strategies, antithrombin, activated protein C, and tissue factor pathway inhibitor have failed to reduce mortality; no specific antisepsis treatments are available [<a href="#rid113">113</a>]. A discussion of sepsis management is presented in detail separately. (See  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates"</a> and  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H1854924"><span class="h2">Sickle cell disease</span><span class="headingEndMark"> — </span>Nitric oxide (NO) metabolism is abnormal in patients with sickle cell disease, both at baseline and during acute illnesses, and may contribute to such complications as the acute chest syndrome (ACS), pulmonary hypertension, and priapism. This may be the result of increased plasma levels of cell-free hemoglobin secondary to hemolysis, which depletes NO. (See  <a class="medical medical_review" href="/d/html/94999.html" rel="external">"Pulmonary hypertension associated with sickle cell disease", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/d/html/7143.html" rel="external">"Priapism and erectile dysfunction in sickle cell disease", section on 'Mechanisms of priapism'</a>.)</p><p>Inhaled NO was investigated as a therapy for ACS but found to be ineffective. (See  <a class="medical medical_review" href="/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)", section on 'Inhaled nitric oxide'</a>.)</p><p class="headingAnchor" id="H1854944"><span class="h2">Idiopathic pulmonary arterial hypertension</span><span class="headingEndMark"> — </span>Endothelin-receptor antagonists may be effective in treating some forms of pulmonary artery hypertension. (See  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.) In the neonate, NO has been used to treat pulmonary hypertension, which may be either idiopathic or part of a cardiovascular or infectious disorder. NO has also been effective in treating hypoxic respiratory failure in term or near-term infants [<a href="#rid114">114</a>]. NO is the only US Food and Drug Administration (FDA)-approved pulmonary vasodilator that can be used during mechanical ventilation [<a href="#rid115">115</a>].</p><p class="headingAnchor" id="H1854964"><span class="h2">Macular degeneration</span><span class="headingEndMark"> — </span>Antiangiogenic approaches directed at inhibiting the action of vascular endothelial growth factor (VEGF) may have a significant impact on the progression of<strong> </strong>age-related macular degeneration.</p><p class="headingAnchor" id="H3041693355"><span class="h2">Diabetic retinopathy</span><span class="headingEndMark"> — </span>Anti-VEGF modalities are standard-of-care options for proliferative diabetic retinopathy and diabetic macular edema [<a href="#rid116">116-118</a>]. (See  <a class="medical medical_review" href="/d/html/1756.html" rel="external">"Diabetic retinopathy: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/1773.html" rel="external">"Diabetic retinopathy: Prevention and treatment"</a>.)</p><p class="headingAnchor" id="H817226232"><span class="h2">Retinopathy of prematurity</span><span class="headingEndMark"> — </span>In premature infants, anti-VEGF is also used to treat retinopathy of prematurity, but further studies are needed to assess potential long-term effects on neurocognitive development and myocardial health [<a href="#rid119">119</a>]. (See  <a class="medical medical_review" href="/d/html/6263.html" rel="external">"Retinopathy of prematurity (ROP): Risk factors, classification, and screening"</a> and  <a class="medical medical_review" href="/d/html/111238.html" rel="external">"Retinopathy of prematurity (ROP): Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H22755429"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Where are they?</strong> – Endothelial cells (ECs) form the lining of all blood and lymphatic vessels within the vascular tree. The adult human body contains at least one trillion endothelial cells, which cover a surface area of &gt;3000 square meters. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What do they do?</strong> – The endothelium mediates vasomotor tone, regulates cellular and nutrient trafficking, maintains blood fluidity, contributes to the local balance between pro- and anti-inflammatory mediators as well as procoagulant and anticoagulant activity, participates in generation of new blood vessels, interacts with circulating blood cells, and undergoes programmed cell death. Each of these activities is dynamically regulated in both space and time. (See <a class="local">'Endothelial heterogeneity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>How are they regulated?</strong> – Because endothelial cells receive cues from a wide variety of cells and tissues, they possess disparate properties that are specific to their local environment. This "heterogeneity" is a central feature of the endothelium, and includes variations in morphology, biosynthetic repertoire, and behavior. (See <a class="local">'Patterns of change in endothelial function'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Endothelial cell disorders can be evaluated in several ways. Placement of catheters within specific vascular beds may allow for proteomic analysis of endothelial cell metabolites or biomarkers. Vasculature can be imaged, and flow can be measured, by Doppler, magnetic resonance angiography, and computed tomography (CT) scanning. Circulating endothelial cells or their shed microparticles can be harvested by direct biopsy or by collecting circulating progenitor cells that can be expanded and studied further in vitro. (See <a class="local">'Evaluation of endothelial disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical relevance</strong> – Some conditions in which endothelial function is disturbed and for which treatments are discussed above, include COVID-19, sepsis, disseminated intravascular coagulation (DIC), acute chest syndrome in sickle cell disease, pulmonary hypertension, and macular degeneration. Gene expression atlases derived from single cell profiling studies may be used to identify functional differences in endothelial cells that could serve as new therapeutic targets. (See <a class="local">'Sepsis as a model endotheliopathy'</a> above and <a class="local">'Treatment of endothelial disorders'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jaffe EA. Cell biology of endothelial cells. Hum Pathol 1987; 18:234.</a></li><li class="breakAll">Cliff WJ. Blood Vessels, Cambridge University Press, New York 1976.</li><li><a class="nounderline abstract_t">Gross PL, Aird WC. The endothelium and thrombosis. Semin Thromb Hemost 2000; 26:463.</a></li><li><a class="nounderline abstract_t">Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111:5271.</a></li><li><a class="nounderline abstract_t">Yano K, Gale D, Massberg S, et al. Phenotypic heterogeneity is an evolutionarily conserved feature of the endothelium. Blood 2007; 109:613.</a></li><li><a class="nounderline abstract_t">Aird WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005; 3:1392.</a></li><li><a class="nounderline abstract_t">Nachman RL, Jaffe EA. Endothelial cell culture: beginnings of modern vascular biology. J Clin Invest 2004; 114:1037.</a></li><li><a class="nounderline abstract_t">Trimm E, Red-Horse K. Vascular endothelial cell development and diversity. Nat Rev Cardiol 2023; 20:197.</a></li><li><a class="nounderline abstract_t">Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2012; 2:a006429.</a></li><li class="breakAll">Hajjar KA. Vascular biology. In: Clinical Hematology, Young NS, Gerson SL, High KA (Eds), Mosby Elsevier, Philadelphia 2006. p.125.</li><li><a class="nounderline abstract_t">Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91:3527.</a></li><li><a class="nounderline abstract_t">Aird WC. Endothelial cell heterogeneity. Crit Care Med 2003; 31:S221.</a></li><li><a class="nounderline abstract_t">Stevens T, Rosenberg R, Aird W, et al. NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am J Physiol Cell Physiol 2001; 281:C1422.</a></li><li><a class="nounderline abstract_t">Aird WC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med 2001; 29:S28.</a></li><li><a class="nounderline abstract_t">Oh P, Li Y, Yu J, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004; 429:629.</a></li><li><a class="nounderline abstract_t">Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380:364.</a></li><li><a class="nounderline abstract_t">Amatschek S, Kriehuber E, Bauer W, et al. Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment. Blood 2007; 109:4777.</a></li><li><a class="nounderline abstract_t">Griffin NM, Schnitzer JE. Chapter 8. Proteomic mapping of the vascular endothelium in vivo for vascular targeting. Methods Enzymol 2008; 445:177.</a></li><li><a class="nounderline abstract_t">Brooks EG, Trotman W, Wadsworth MP, et al. Valves of the deep venous system: an overlooked risk factor. Blood 2009; 114:1276.</a></li><li><a class="nounderline abstract_t">Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004; 104:840.</a></li><li><a class="nounderline abstract_t">Weninger W, Ulfman LH, Cheng G, et al. Specialized contributions by alpha(1,3)-fucosyltransferase-IV and FucT-VII during leukocyte rolling in dermal microvessels. Immunity 2000; 12:665.</a></li><li><a class="nounderline abstract_t">Dekker RJ, van Soest S, Fontijn RD, et al. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2). Blood 2002; 100:1689.</a></li><li><a class="nounderline abstract_t">Ungvari Z, Tarantini S, Kiss T, et al. Endothelial dysfunction and angiogenesis impairment in the ageing vasculature. Nat Rev Cardiol 2018; 15:555.</a></li><li><a class="nounderline abstract_t">Florey . The endothelial cell. Br Med J 1966; 2:487.</a></li><li><a class="nounderline abstract_t">Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180:1332.</a></li><li class="breakAll">Endothelial Dysfunction and the Pathogenesis of Atherosclerosis, Gimbrone MA Jr (Ed), Springer-Verlag, New York 1980.</li><li><a class="nounderline abstract_t">Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046.</a></li><li><a class="nounderline abstract_t">Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251:788.</a></li><li><a class="nounderline abstract_t">Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59:1203.</a></li><li><a class="nounderline abstract_t">Hasstedt SJ, Bezemer ID, Callas PW, et al. Cell adhesion molecule 1: a novel risk factor for venous thrombosis. Blood 2009; 114:3084.</a></li><li class="breakAll">Hajjar KA, Muller WA. Chapter 114: Vascular function in hemostasis. In Williams Hematology, 10th ed, Kaushansky K, Prchal JT, Burns LJ, Lichtman MA, Levi M, Linch DC (Eds), McGraw Hill, 2021. p.2067.</li><li><a class="nounderline abstract_t">Fassel H, Chen H, Ruisi M, et al. Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism. Blood 2021; 137:2221.</a></li><li><a class="nounderline abstract_t">Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respir Med 2020; 8:433.</a></li><li><a class="nounderline abstract_t">Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020; 383:2451.</a></li><li><a class="nounderline abstract_t">Fauci AS, Lane HC, Redfield RR. Covid-19 - Navigating the Uncharted. N Engl J Med 2020; 382:1268.</a></li><li><a class="nounderline abstract_t">Wadman M, Couzin-Frankel J, Kaiser J, Matacic C. A rampage through the body. Science 2020; 368:356.</a></li><li><a class="nounderline abstract_t">Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395:1417.</a></li><li><a class="nounderline abstract_t">Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383:120.</a></li><li><a class="nounderline abstract_t">Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020; 220:1.</a></li><li><a class="nounderline abstract_t">Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801.</a></li><li><a class="nounderline abstract_t">Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101:3765.</a></li><li><a class="nounderline abstract_t">Lemichez E, Lecuit M, Nassif X, Bourdoulous S. Breaking the wall: targeting of the endothelium by pathogenic bacteria. Nat Rev Microbiol 2010; 8:93.</a></li><li><a class="nounderline abstract_t">Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med 2010; 363:689.</a></li><li><a class="nounderline abstract_t">Volk T, Kox WJ. Endothelium function in sepsis. Inflamm Res 2000; 49:185.</a></li><li><a class="nounderline abstract_t">Faure E, Thomas L, Xu H, et al. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001; 166:2018.</a></li><li><a class="nounderline abstract_t">Henneke P, Golenbock DT. Innate immune recognition of lipopolysaccharide by endothelial cells. Crit Care Med 2002; 30:S207.</a></li><li><a class="nounderline abstract_t">Zhang FX, Kirschning CJ, Mancinelli R, et al. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999; 274:7611.</a></li><li><a class="nounderline abstract_t">Zhao B, Bowden RA, Stavchansky SA, Bowman PD. Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays. Am J Physiol Cell Physiol 2001; 281:C1587.</a></li><li><a class="nounderline abstract_t">Brown KA, Brain SD, Pearson JD, et al. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368:157.</a></li><li><a class="nounderline abstract_t">Vallet B, Wiel E. Endothelial cell dysfunction and coagulation. Crit Care Med 2001; 29:S36.</a></li><li><a class="nounderline abstract_t">Lacroix R, Sabatier F, Mialhe A, et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood 2007; 110:2432.</a></li><li><a class="nounderline abstract_t">Drake TA, Cheng J, Chang A, Taylor FB Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142:1458.</a></li><li><a class="nounderline abstract_t">Lupu C, Westmuckett AD, Peer G, et al. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol 2005; 167:1161.</a></li><li><a class="nounderline abstract_t">Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408.</a></li><li><a class="nounderline abstract_t">Ishii H, Salem HH, Bell CE, et al. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986; 67:362.</a></li><li><a class="nounderline abstract_t">Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89:2429.</a></li><li><a class="nounderline abstract_t">Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008; 359:1261.</a></li><li><a class="nounderline abstract_t">Chen D, Giannopoulos K, Shiels PG, et al. Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. Blood 2004; 104:1344.</a></li><li><a class="nounderline abstract_t">Aird WC, Mosnier LO, Fairhurst RM. Plasmodium falciparum picks (on) EPCR. Blood 2014; 123:163.</a></li><li><a class="nounderline abstract_t">Weiler H, Lindner V, Kerlin B, et al. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol 2001; 21:1531.</a></li><li><a class="nounderline abstract_t">Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 2002; 99:2455.</a></li><li><a class="nounderline abstract_t">André P. P-selectin in haemostasis. Br J Haematol 2004; 126:298.</a></li><li><a class="nounderline abstract_t">Miyasaka M, Tanaka T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat Rev Immunol 2004; 4:360.</a></li><li><a class="nounderline abstract_t">Ley K. Integration of inflammatory signals by rolling neutrophils. Immunol Rev 2002; 186:8.</a></li><li><a class="nounderline abstract_t">Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992; 26:48.</a></li><li><a class="nounderline abstract_t">Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol Ther 2001; 91:179.</a></li><li><a class="nounderline abstract_t">Crawford JH, Chacko BK, Pruitt HM, et al. Transduction of NO-bioactivity by the red blood cell in sepsis: novel mechanisms of vasodilation during acute inflammatory disease. Blood 2004; 104:1375.</a></li><li><a class="nounderline abstract_t">Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med 2010; 363:689.</a></li><li><a class="nounderline abstract_t">Yano K, Liaw PC, Mullington JM, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006; 203:1447.</a></li><li><a class="nounderline abstract_t">Parikh SM. Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS. Virulence 2013; 4:517.</a></li><li><a class="nounderline abstract_t">Parikh SM. Angiopoietins and Tie2 in vascular inflammation. Curr Opin Hematol 2017; 24:432.</a></li><li><a class="nounderline abstract_t">Ushiyama A, Kataoka H, Iijima T. Glycocalyx and its involvement in clinical pathophysiologies. J Intensive Care 2016; 4:59.</a></li><li><a class="nounderline abstract_t">Martin L, Koczera P, Zechendorf E, Schuerholz T. The Endothelial Glycocalyx: New Diagnostic and Therapeutic Approaches in Sepsis. Biomed Res Int 2016; 2016:3758278.</a></li><li><a class="nounderline abstract_t">Luo M, Flood EC, Almeida D, et al. Annexin A2 supports pulmonary microvascular integrity by linking vascular endothelial cadherin and protein tyrosine phosphatases. J Exp Med 2017; 214:2535.</a></li><li><a class="nounderline abstract_t">Lindner H, Holler E, Ertl B, et al. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. Blood 1997; 89:1931.</a></li><li><a class="nounderline abstract_t">Bombeli T, Schwartz BR, Harlan JM. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 1999; 93:3831.</a></li><li><a class="nounderline abstract_t">McCuskey RS, Urbaschek R, Urbaschek B. The microcirculation during endotoxemia. Cardiovasc Res 1996; 32:752.</a></li><li><a class="nounderline abstract_t">Amersfoort J, Eelen G, Carmeliet P. Immunomodulation by endothelial cells - partnering up with the immune system? Nat Rev Immunol 2022; 22:576.</a></li><li><a class="nounderline abstract_t">Brooimans RA, van Wieringen PA, van Es LA, Daha MR. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis. Eur J Immunol 1992; 22:3135.</a></li><li><a class="nounderline abstract_t">Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 2012; 217:195.</a></li><li><a class="nounderline abstract_t">Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:340.</a></li><li><a class="nounderline abstract_t">Pottiez G, Flahaut C, Cecchelli R, Karamanos Y. Understanding the blood-brain barrier using gene and protein expression profiling technologies. Brain Res Rev 2009; 62:83.</a></li><li><a class="nounderline abstract_t">Karamanos Y, Pottiez G. Proteomics and the blood-brain barrier: how recent findings help drug development. Expert Rev Proteomics 2016; 13:251.</a></li><li><a class="nounderline abstract_t">Baird AE, Wright VL. Vascular biology: cellular and molecular profiling. Semin Neurol 2006; 26:65.</a></li><li><a class="nounderline abstract_t">Mori N, Natarajan K, Chacko VP, et al. Choline phospholipid metabolites of human vascular endothelial cells altered by cyclooxygenase inhibition, growth factor depletion, and paracrine factors secreted by cancer cells. Mol Imaging 2003; 2:124.</a></li><li><a class="nounderline abstract_t">Padera TP, Stoll BR, So PT, Jain RK. Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions. Mol Imaging 2002; 1:9.</a></li><li><a class="nounderline abstract_t">Blann AD, Woywodt A, Bertolini F, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005; 93:228.</a></li><li><a class="nounderline abstract_t">Chirinos JA, Heresi GA, Velasquez H, et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 2005; 45:1467.</a></li><li><a class="nounderline abstract_t">Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109:1801.</a></li><li><a class="nounderline abstract_t">Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol 2007; 137:36.</a></li><li><a class="nounderline abstract_t">Deregibus MC, Cantaluppi V, Calogero R, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007; 110:2440.</a></li><li><a class="nounderline abstract_t">Ghosh A, Li W, Febbraio M, et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 2008; 118:1934.</a></li><li><a class="nounderline abstract_t">Shantsila E, Blann AD, Lip GY. Circulating endothelial cells: from bench to clinical practice. J Thromb Haemost 2008; 6:865.</a></li><li><a class="nounderline abstract_t">Mancuso P, Antoniotti P, Quarna J, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 2009; 15:267.</a></li><li><a class="nounderline abstract_t">Tilki D, Hohn HP, Ergün B, et al. Emerging biology of vascular wall progenitor cells in health and disease. Trends Mol Med 2009; 15:501.</a></li><li><a class="nounderline abstract_t">Körbling M, Reuben JM, Gao H, et al. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 2006; 46:1795.</a></li><li><a class="nounderline abstract_t">Bidot L, Jy W, Bidot C Jr, et al. Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis. J Thromb Haemost 2008; 6:913.</a></li><li><a class="nounderline abstract_t">Ridger VC, Boulanger CM, Angelillo-Scherrer A, et al. Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. Thromb Haemost 2017; 117:1296.</a></li><li><a class="nounderline abstract_t">Chironi GN, Boulanger CM, Simon A, et al. Endothelial microparticles in diseases. Cell Tissue Res 2009; 335:143.</a></li><li><a class="nounderline abstract_t">Erdbruegger U, Woywodt A, Kirsch T, et al. Circulating endothelial cells as a prognostic marker in thrombotic microangiopathy. Am J Kidney Dis 2006; 48:564.</a></li><li><a class="nounderline abstract_t">Woywodt A, Goldberg C, Kirsch T, et al. Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis. Ann Rheum Dis 2006; 65:164.</a></li><li><a class="nounderline abstract_t">Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337:1584.</a></li><li><a class="nounderline abstract_t">Mutin M, Canavy I, Blann A, et al. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93:2951.</a></li><li><a class="nounderline abstract_t">Widemann A, Sabatier F, Arnaud L, et al. CD146-based immunomagnetic enrichment followed by multiparameter flow cytometry: a new approach to counting circulating endothelial cells. J Thromb Haemost 2008; 6:869.</a></li><li><a class="nounderline abstract_t">Jourde-Chiche N, Dou L, Sabatier F, et al. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost 2009; 7:1576.</a></li><li><a class="nounderline abstract_t">Georgescu A, Alexandru N, Popov D, et al. Chronic venous insufficiency is associated with elevated level of circulating microparticles. J Thromb Haemost 2009; 7:1566.</a></li><li><a class="nounderline abstract_t">Tabit CE, Shenouda SM, Holbrook M, et al. Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 2013; 127:86.</a></li><li><a class="nounderline abstract_t">Hebbel RP. Blood endothelial cells: utility from ambiguity. J Clin Invest 2017; 127:1613.</a></li><li><a class="nounderline abstract_t">Starke RD, Paschalaki KE, Dyer CE, et al. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells. Blood 2013; 121:2773.</a></li><li><a class="nounderline abstract_t">Wang JW, Bouwens EA, Pintao MC, et al. Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease. Blood 2013; 121:2762.</a></li><li><a class="nounderline abstract_t">Enenstein J, Milbauer L, Domingo E, et al. Proinflammatory phenotype with imbalance of KLF2 and RelA: risk of childhood stroke with sickle cell anemia. Am J Hematol 2010; 85:18.</a></li><li><a class="nounderline abstract_t">Paschalaki KE, Randi AM. Recent Advances in Endothelial Colony Forming Cells Toward Their Use in Clinical Translation. Front Med (Lausanne) 2018; 5:295.</a></li><li><a class="nounderline abstract_t">Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. Lancet Infect Dis 2015; 15:581.</a></li><li><a class="nounderline abstract_t">Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2017; 1:CD000399.</a></li><li><a class="nounderline abstract_t">Davis MD, Donn SM, Ward RM. Administration of Inhaled Pulmonary Vasodilators to the Mechanically Ventilated Neonatal Patient. Paediatr Drugs 2017; 19:183.</a></li><li><a class="nounderline abstract_t">Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World J Diabetes 2016; 7:333.</a></li><li><a class="nounderline abstract_t">Ajlan RS, Silva PS, Sun JK. Vascular Endothelial Growth Factor and Diabetic Retinal Disease. Semin Ophthalmol 2016; 31:40.</a></li><li><a class="nounderline abstract_t">Dhoot DS, Avery RL. Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy. Curr Diab Rep 2016; 16:122.</a></li><li><a class="nounderline abstract_t">Sankar MJ, Sankar J, Mehta M, et al. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2016; 2:CD009734.</a></li></ol></div><div id="topicVersionRevision">Topic 1330 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3546072" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cell biology of endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3546072" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cell biology of endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11129402" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The endothelium and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18502843" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The vessel wall and its interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990601" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Phenotypic heterogeneity is an evolutionarily conserved feature of the endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15892866" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Spatial and temporal dynamics of the endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489946" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Endothelial cell culture: beginnings of modern vascular biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36198871" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Vascular endothelial cell development and diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315715" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Endothelial cell heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315715" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Endothelial cell heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9572988" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endothelial cells in physiology and in the pathophysiology of vascular disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682444" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Endothelial cell heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600404" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445731" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15190345" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598934" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Organ targeting in vivo using phage display peptide libraries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17289814" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19022060" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chapter 8. Proteomic mapping of the vascular endothelium in vivo for vascular targeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436051" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Valves of the deep venous system: an overlooked risk factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073034" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894166" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Specialized contributions by alpha(1,3)-fucosyltransferase-IV and FucT-VII during leukocyte rolling in dermal microvessels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176889" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29795441" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Endothelial dysfunction and angiogenesis impairment in the ageing vasculature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5913081" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The endothelial cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4350926" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4350926" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3093861" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1990440" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2688898" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643986" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cell adhesion molecule 1: a novel risk factor for venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643986" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cell adhesion molecule 1: a novel risk factor for venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512476" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203709" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment for severe acute respiratory distress syndrome from COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32412710" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Severe Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109011" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Covid-19 - Navigating the Uncharted.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32327580" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A rampage through the body.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32325026" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Endothelial cell infection and endotheliitis in COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32437596" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32299776" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903338" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543869" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20040916" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Breaking the wall: targeting of the endothelium by pathogenic bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818861" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sepsis and endothelial permeability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893041" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Endothelium function in sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11160251" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12004237" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Innate immune recognition of lipopolysaccharide by endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10075645" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600422" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16829300" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Neutrophils in development of multiple organ failure in sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445732" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Endothelial cell dysfunction and coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606760" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7684196" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192650" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496851" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dysfunction of endothelial protein C activation in severe meningococcal sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3002524" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9116287" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Apoptotic vascular endothelial cells become procoagulant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799560" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Platelets, petechiae, and preservation of the vascular wall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126322" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24246501" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Plasmodium falciparum picks (on) EPCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11557684" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Characterization of a mouse model for thrombomodulin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895779" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15257701" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : P-selectin in haemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15122201" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Lymphocyte trafficking across high endothelial venules: dogmas and enigmas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12234358" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Integration of inflammatory signals by rolling neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516112" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Protective and pathological roles of nitric oxide in endotoxin shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11744067" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Is nitric oxide overproduction the target of choice for the management of septic shock?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150083" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Transduction of NO-bioactivity by the red blood cell in sepsis: novel mechanisms of vasodilation during acute inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818861" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sepsis and endothelial permeability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702604" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23652985" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28582314" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Angiopoietins and Tie2 in vascular inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27617097" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Glycocalyx and its involvement in clinical pathophysiologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27699168" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The Endothelial Glycocalyx: New Diagnostic and Therapeutic Approaches in Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28694388" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Annexin A2 supports pulmonary microvascular integrity by linking vascular endothelial cadherin and protein tyrosine phosphatases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9058713" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10339490" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8915193" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The microcirculation during endotoxemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35288707" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Immunomodulation by endothelial cells - partnering up with the immune system?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1280224" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855165" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15054046" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770003" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Understanding the blood-brain barrier using gene and protein expression profiling technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26778576" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Proteomics and the blood-brain barrier: how recent findings help drug development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16479445" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Vascular biology: cellular and molecular profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12964309" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Choline phospholipid metabolites of human vascular endothelial cells altered by cyclooxygenase inhibition, growth factor depletion, and paracrine factors secreted by cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920856" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15711737" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Circulating endothelial cells. Biomarker of vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15862420" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053059" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17359370" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Plasma microparticles and vascular disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17536014" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18431509" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18221356" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Circulating endothelial cells: from bench to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118054" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19828379" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Emerging biology of vascular wall progenitor cells in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17002637" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18363818" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28569921" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18989704" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Endothelial microparticles in diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997052" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Circulating endothelial cells as a prognostic marker in thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150786" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371854" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Circulating activated endothelial cells in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216090" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284598" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : CD146-based immunomagnetic enrichment followed by multiparameter flow cytometry: a new approach to counting circulating endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19583820" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19552639" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Chronic venous insufficiency is associated with elevated level of circulating microparticles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23204109" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Protein kinase C-βcontributes to impaired endothelial insulin signaling in humans with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28459428" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Blood endothelial cells: utility from ambiguity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23355534" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426949" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19957349" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Proinflammatory phenotype with imbalance of KLF2 and RelA: risk of childhood stroke with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30406106" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Recent Advances in Endothelial Colony Forming Cells Toward Their Use in Clinical Translation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25932591" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Sepsis: a roadmap for future research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056166" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Nitric oxide for respiratory failure in infants born at or near term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28374138" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Administration of Inhaled Pulmonary Vasodilators to the Mechanically Ventilated Neonatal Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27625747" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Treatment of diabetic retinopathy: Recent advances and unresolved challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26959128" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Vascular Endothelial Growth Factor and Diabetic Retinal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27766582" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26932750" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
